Furthermore, our data showed that the downregulation of MyD88 expression could significantly enhance PTX chemosensitivity in both breast cancer MCF-7 cells, lung cancer A549 cells (4), and ovarian cancer A2780 cells (5). Here, MYD88 is linked to breast carcinoma.